Search

Displaying results 6211 - 6220 of 10000 in total
  1. Drug

    OTI-030

    go.drugbank.com/drugs/DB05648
    Investigational

  2. Drug

    Iodofiltic acid I-123

    go.drugbank.com/drugs/DB05683
    Investigational

    Synonyms: I-123 BMIPP, Iodofiltic acid I 123
  3. Drug

    R-1487

    go.drugbank.com/drugs/DB06518
    Experimental

  4. Drug

    Rhus Glabra Pollen

    go.drugbank.com/drugs/DB13895
    Approved

    Rhus Glabra Pollen pollen is the pollen of the Rhus Glabra Pollen plant. The pollen is mainly used in allergenic testing.

  5. Drug

    Quercus alba pollen

    go.drugbank.com/drugs/DB10376
    Approved

    It can be subcutaneously administered to initiate an immune response in case of an allergic reaction. … Quercus alba pollen, or oak white pollen, is a non-standardized allergen extract used for the diagnosis and treatment of allergic disease to grass pollen.

    Products: Center-AL - Quercus Alba Pollen
  6. Drug

    Prolgolimab

    go.drugbank.com/drugs/DB16740
    Investigational

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
  7. Drug

    Ethyl biscoumacetate

    go.drugbank.com/drugs/DB08794
    ApprovedWithdrawn

    Ethyl biscoumacetate is a courmarin that is used as an anticoagulant. It has actions similar to those of Warfarin. (From Martindale, The Extra Pharmacopoeia, 30th ed, p226)

  8. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. … In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain.

  9. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    RPI-78M is being developed for the treatment of multiple sclerosis (MS).

  10. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. … However, it presents a five-fold preference for the MAO-B subtype.